419 related articles for article (PubMed ID: 27587950)
1. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
Kim H; Kim S; Lee HH; Heo H
Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950
[TBL] [Abstract][Full Text] [Related]
2. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
Heo H; Kim S; Lee HH; Cho HR; Xu WJ; Lee SH; Park CK; Park S; Choi SH; Kim H
PLoS One; 2016; 11(1):e0147794. PubMed ID: 26820720
[TBL] [Abstract][Full Text] [Related]
3. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
[TBL] [Abstract][Full Text] [Related]
5. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
[TBL] [Abstract][Full Text] [Related]
9. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
Andronesi OC; Rapalino O; Gerstner E; Chi A; Batchelor TT; Cahill DP; Sorensen AG; Rosen BR
J Clin Invest; 2013 Sep; 123(9):3659-63. PubMed ID: 23999439
[TBL] [Abstract][Full Text] [Related]
10. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
11. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
Cuccarini V; Antelmi L; Pollo B; Paterra R; Calatozzolo C; Nigri A; DiMeco F; Eoli M; Finocchiaro G; Brenna G; Tramacere I; Bruzzone MG; Anghileri E
Neurol Sci; 2020 Feb; 41(2):347-355. PubMed ID: 31650436
[TBL] [Abstract][Full Text] [Related]
12. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
[TBL] [Abstract][Full Text] [Related]
13. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Kalinina J; Carroll A; Wang L; Yu Q; Mancheno DE; Wu S; Liu F; Ahn J; He M; Mao H; Van Meir EG
J Mol Med (Berl); 2012 Oct; 90(10):1161-1171. PubMed ID: 22426639
[TBL] [Abstract][Full Text] [Related]
14. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
[TBL] [Abstract][Full Text] [Related]
16. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513
[TBL] [Abstract][Full Text] [Related]
17. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
[TBL] [Abstract][Full Text] [Related]
18. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.
Bertolino N; Marchionni C; Ghielmetti F; Burns B; Finocchiaro G; Anghileri E; Bruzzone MG; Minati L
Phys Med; 2014 Sep; 30(6):702-7. PubMed ID: 24685182
[TBL] [Abstract][Full Text] [Related]
20. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
Branzoli F; Di Stefano AL; Capelle L; Ottolenghi C; Valabrègue R; Deelchand DK; Bielle F; Villa C; Baussart B; Lehéricy S; Sanson M; Marjanska M
Neuro Oncol; 2018 Jun; 20(7):907-916. PubMed ID: 29126125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
